JP2021532063A5 - - Google Patents
Info
- Publication number
- JP2021532063A5 JP2021532063A5 JP2020567044A JP2020567044A JP2021532063A5 JP 2021532063 A5 JP2021532063 A5 JP 2021532063A5 JP 2020567044 A JP2020567044 A JP 2020567044A JP 2020567044 A JP2020567044 A JP 2020567044A JP 2021532063 A5 JP2021532063 A5 JP 2021532063A5
- Authority
- JP
- Japan
- Prior art keywords
- groups
- alkyl
- antibody
- cancer
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023196433A JP7753317B2 (ja) | 2018-06-01 | 2023-11-20 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
| JP2025165244A JP2026004432A (ja) | 2018-06-01 | 2025-10-01 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679672P | 2018-06-01 | 2018-06-01 | |
| US201862679631P | 2018-06-01 | 2018-06-01 | |
| US62/679,631 | 2018-06-01 | ||
| US62/679,672 | 2018-06-01 | ||
| US201862779324P | 2018-12-13 | 2018-12-13 | |
| US62/779,324 | 2018-12-13 | ||
| PCT/US2019/035015 WO2019232449A1 (en) | 2018-06-01 | 2019-05-31 | Splicing modulator antibody-drug conjugates and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023196433A Division JP7753317B2 (ja) | 2018-06-01 | 2023-11-20 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532063A JP2021532063A (ja) | 2021-11-25 |
| JP2021532063A5 true JP2021532063A5 (enExample) | 2022-06-06 |
| JP7390315B2 JP7390315B2 (ja) | 2023-12-01 |
Family
ID=66999916
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567044A Active JP7390315B2 (ja) | 2018-06-01 | 2019-05-31 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
| JP2023196433A Active JP7753317B2 (ja) | 2018-06-01 | 2023-11-20 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
| JP2025165244A Pending JP2026004432A (ja) | 2018-06-01 | 2025-10-01 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023196433A Active JP7753317B2 (ja) | 2018-06-01 | 2023-11-20 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
| JP2025165244A Pending JP2026004432A (ja) | 2018-06-01 | 2025-10-01 | スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US12172986B2 (enExample) |
| EP (1) | EP3801632A1 (enExample) |
| JP (3) | JP7390315B2 (enExample) |
| KR (1) | KR20210016375A (enExample) |
| CN (5) | CN119405832A (enExample) |
| AU (1) | AU2019277700B2 (enExample) |
| BR (1) | BR112020024549A2 (enExample) |
| CA (1) | CA3099920A1 (enExample) |
| CL (8) | CL2020003117A1 (enExample) |
| CO (1) | CO2020016137A2 (enExample) |
| IL (3) | IL279062B2 (enExample) |
| JO (3) | JOP20200268A1 (enExample) |
| MX (1) | MX2020012997A (enExample) |
| PE (1) | PE20211220A1 (enExample) |
| PH (1) | PH12020500672A1 (enExample) |
| SG (1) | SG11202010341PA (enExample) |
| TW (2) | TW202519520A (enExample) |
| WO (1) | WO2019232449A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200058540A (ko) | 2017-10-02 | 2020-05-27 | 비스테라, 인크. | Cd138에 대한 항체 분자 및 이의 용도 |
| EP3801523B1 (en) | 2018-06-01 | 2024-09-11 | Eisai R&D Management Co., Ltd. | Splicing modulators |
| CN119405832A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| SG11202102419VA (en) | 2018-12-13 | 2021-04-29 | Eisai R&D Man Co Ltd | Herboxidiene splicing modulator antibody-drug conjugates and methods of use |
| EP3918069A1 (en) | 2019-01-31 | 2021-12-08 | Bar Ilan University | Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy |
| GB201905780D0 (en) * | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
| MY210065A (en) | 2019-06-17 | 2025-08-25 | Visterra Inc | Humanized antibody molecules to cd138 and uses thereof |
| WO2021090062A1 (en) | 2019-11-07 | 2021-05-14 | Eisai R&D Management Co., Ltd. | Anti-mesothelin eribulin antibody-drug conjugates and methods of use |
| EP4088739A4 (en) * | 2019-12-23 | 2024-11-13 | Eisai R&D Management Co., Ltd. | PROCESS FOR PRODUCING ANTIBODY-DRUG CONJUGATE BASED ON ERIBULIN |
| BR112022019532A2 (pt) * | 2020-03-31 | 2022-12-06 | Orum Therapeutics Inc | Conjugados de neodegrader |
| AU2021284401A1 (en) * | 2020-06-05 | 2023-01-05 | Eisai R&D Management Co., Ltd. | Anti-BCMA antibody-drug conjugates and methods of use |
| US20240043928A1 (en) | 2020-11-04 | 2024-02-08 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| JP2024519907A (ja) * | 2021-05-21 | 2024-05-21 | レメゲン シーオー．，エルティーディー． | 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用 |
| WO2023097254A1 (en) * | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| CN114573698B (zh) * | 2022-03-16 | 2023-01-06 | 沈阳三生制药有限责任公司 | 一种FcRn抗原结合蛋白及其制备方法和应用 |
| CN115974976B (zh) * | 2022-11-23 | 2024-06-04 | 华中科技大学 | 拮抗多肽及用于制备抗急性肾损伤药物的应用 |
| KR20250169306A (ko) | 2023-04-18 | 2025-12-02 | 아스트라제네카 아베 | 절단가능한 링커를 포함하는 접합체 |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
| WO2025132978A1 (en) * | 2023-12-19 | 2025-06-26 | BioNTech SE | Cfc1 binding molecule |
| TW202542189A (zh) * | 2023-12-19 | 2025-11-01 | 德商拜恩技術股份公司 | Cfc1結合分子 |
| WO2025240362A1 (en) * | 2024-05-13 | 2025-11-20 | The Board Of Trustees Of The Leland Stanford Junior University | Discovery of enpp3 as a cgamp hydrolase with a role in anti-cancer immunity |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| CA2109528A1 (en) | 1991-05-01 | 1992-11-02 | Gregory A. Prince | A method for treating infectious respiratory diseases |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| AU705688B2 (en) | 1995-11-10 | 1999-05-27 | Cytogen Corporation | Peptides which enhance transport across tissues and methods of identifying and using the same |
| DK0871490T3 (da) | 1995-12-22 | 2003-07-07 | Bristol Myers Squibb Co | Forgrenede hydrazonlinkere |
| ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| CA2277801C (en) | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| WO1999066903A2 (en) | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US7555503B1 (en) | 2000-06-30 | 2009-06-30 | Click Commerce, Inc. | Method and apparatus for managing updates to a catalog |
| TWI312681B (en) | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| PL207087B1 (pl) | 2001-04-26 | 2010-10-29 | Biogen | Przeciwciało, które wiąże się swoiście z białkiem Cripto, zawierająca je kompozycja farmaceutyczna i zastosowanie przeciwciała |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| CA2494536C (en) | 2002-07-31 | 2011-10-04 | Mercian Corporation | A 12-membered ring macrolide active substance |
| JP4459051B2 (ja) | 2002-07-31 | 2010-04-28 | メルシャン株式会社 | 新規生理活性物質 |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| WO2005075681A1 (ja) | 2004-02-06 | 2005-08-18 | Eisai R & D Management Co., Ltd. | 抗癌剤に対する癌細胞の感受性を検定する方法 |
| EP3101034A1 (en) | 2004-02-12 | 2016-12-07 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| NZ579482A (en) | 2004-06-01 | 2011-02-25 | Genentech Inc | Antibody drug conjugates and methods |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| JP4993645B2 (ja) | 2004-12-01 | 2012-08-08 | ジェネンテック， インコーポレイテッド | 抗体薬剤結合体および方法 |
| EP1928912A4 (en) | 2005-09-07 | 2010-02-24 | Medimmune Inc | EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS |
| JPWO2007043621A1 (ja) | 2005-10-13 | 2009-04-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライドｂ及びプラジエノライドｄの全合成方法 |
| EP2053393A1 (en) | 2006-08-02 | 2009-04-29 | Eisai R&D Management Co., Ltd. | Pladienolide target molecule, compound capable of binding to the target molecule, and screening method for the compound |
| BRPI0717638A2 (pt) | 2006-10-27 | 2013-11-12 | Genentech Inc | Anticorpors e imunoconjugados e usos para os mesmos |
| US7790887B2 (en) | 2007-01-29 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same |
| WO2008111464A1 (ja) | 2007-03-05 | 2008-09-18 | Eisai R & D Management Co., Ltd. | スプライシング異常を指標とする抗ガン剤の作用検定方法 |
| WO2009008492A1 (ja) | 2007-07-06 | 2009-01-15 | Eisai R & D Management Co., Ltd. | マクロライド系化合物の製造方法およびその製造中間体 |
| US8653283B2 (en) | 2009-04-17 | 2014-02-18 | The Regents Of The University Of California | Anticancer agents |
| JPWO2011074621A1 (ja) | 2009-12-18 | 2013-04-25 | 株式会社医学生物学研究所 | メソセリン（ｍｓｌｎ）に対する抗体及びその用途 |
| US9056910B2 (en) | 2012-05-01 | 2015-06-16 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| CN104640572B (zh) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物，偶联方法，及其用途 |
| US20140069822A1 (en) | 2012-09-10 | 2014-03-13 | Antec Leyden B.V. | Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction |
| US9155357B2 (en) | 2012-09-11 | 2015-10-13 | Nike, Inc. | Automated strobel printing |
| CN105121421B (zh) * | 2012-11-05 | 2020-10-02 | 辉瑞公司 | 司普力西欧他汀类似物 |
| US20140275010A1 (en) | 2013-03-12 | 2014-09-18 | Guo Zhu Zheng | Quaternary salts |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| CN105517577A (zh) | 2013-06-21 | 2016-04-20 | 先天制药公司 | 多肽的酶促偶联 |
| WO2015015448A2 (en) | 2013-07-31 | 2015-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
| CA2919790C (en) | 2013-08-02 | 2018-06-19 | Pfizer Inc. | Anti-cxcr4 antibodies and antibody-drug conjugates |
| CA2924398A1 (en) | 2013-11-05 | 2015-05-14 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
| IL310627B2 (en) | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| PT3134127T (pt) | 2014-04-25 | 2020-04-09 | Rinat Neuroscience Corp | Conjugados de anticorpo-fármaco com alta carga de fármaco |
| LT3143016T (lt) | 2014-05-15 | 2019-06-10 | Eisai R&D Management Co., Ltd. | Pladienolido piridino junginiai ir panaudojimo būdai |
| JP6349171B2 (ja) | 2014-07-07 | 2018-06-27 | ローム株式会社 | ノイズ除去回路、タイミングコントローラ、ディスプレイ装置、電子機器、ソースドライバの制御方法 |
| RU2715038C2 (ru) | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
| PL3185908T3 (pl) | 2014-08-28 | 2020-09-07 | Pfizer Inc. | Łączniki modulujące stabilność do stosowania z koniugatami przeciwciało-lek |
| UY36519A (es) | 2015-01-16 | 2016-08-31 | Hope City | Anticuerpos de penetración celular |
| TWI703159B (zh) | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| WO2017011803A1 (en) * | 2015-07-16 | 2017-01-19 | Cellerant Therapeutics, Inc. | Cysteine-substituted immunoglobulins |
| JP6876680B2 (ja) | 2015-09-01 | 2021-05-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
| BR112018009995B1 (pt) | 2015-11-18 | 2024-04-30 | Eisai R&D Management Co., Ltd | Forma cristalina, composição farmacêutica, e, uso da forma cristalina |
| TWI727380B (zh) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| CN109219618B (zh) | 2016-01-21 | 2022-08-09 | 辉瑞大药厂 | 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途 |
| PE20231050A1 (es) | 2016-03-02 | 2023-07-11 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso |
| CN105669800B (zh) | 2016-03-03 | 2017-12-15 | 湖南省农产品加工研究所 | 一种从柑橘中联合提取精油、果胶、橙皮苷、辛弗林和柠檬苦素的方法 |
| EP3464379B1 (en) | 2016-06-06 | 2023-09-27 | Abzena (UK) Limited | Antibodies, uses thereof and conjugates thereof |
| KR20220150408A (ko) | 2016-11-14 | 2022-11-10 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
| EP3694887A4 (en) | 2017-10-13 | 2022-02-23 | A & G Pharmaceutical, Inc. | MONOCLONAL ANTIBODIES AND CONJUGATES TO PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF |
| SG11202009906TA (en) | 2018-04-09 | 2020-11-27 | Eisai R&D Man Co Ltd | Pladienolide compounds and their use |
| CA3096424A1 (en) | 2018-04-12 | 2019-10-17 | Eisai R&D Management Co., Ltd. | Pladienolide derivatives as spliceosome targeting agents for treating cancer |
| CN119405832A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| EP3801523B1 (en) | 2018-06-01 | 2024-09-11 | Eisai R&D Management Co., Ltd. | Splicing modulators |
| SG11202102419VA (en) | 2018-12-13 | 2021-04-29 | Eisai R&D Man Co Ltd | Herboxidiene splicing modulator antibody-drug conjugates and methods of use |
| WO2021090062A1 (en) | 2019-11-07 | 2021-05-14 | Eisai R&D Management Co., Ltd. | Anti-mesothelin eribulin antibody-drug conjugates and methods of use |
| JP7821733B2 (ja) | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
| AU2021284401A1 (en) | 2020-06-05 | 2023-01-05 | Eisai R&D Management Co., Ltd. | Anti-BCMA antibody-drug conjugates and methods of use |
-
2019
- 2019-05-31 CN CN202411513187.5A patent/CN119405832A/zh active Pending
- 2019-05-31 CN CN202411513294.8A patent/CN119405834A/zh active Pending
- 2019-05-31 JP JP2020567044A patent/JP7390315B2/ja active Active
- 2019-05-31 PE PE2020001954A patent/PE20211220A1/es unknown
- 2019-05-31 CN CN202411513264.7A patent/CN119405833A/zh active Pending
- 2019-05-31 TW TW114103019A patent/TW202519520A/zh unknown
- 2019-05-31 CN CN202411513167.8A patent/CN119405831A/zh active Pending
- 2019-05-31 JO JOP/2020/0268A patent/JOP20200268A1/ar unknown
- 2019-05-31 MX MX2020012997A patent/MX2020012997A/es unknown
- 2019-05-31 US US17/059,635 patent/US12172986B2/en active Active
- 2019-05-31 AU AU2019277700A patent/AU2019277700B2/en active Active
- 2019-05-31 IL IL279062A patent/IL279062B2/en unknown
- 2019-05-31 SG SG11202010341PA patent/SG11202010341PA/en unknown
- 2019-05-31 CA CA3099920A patent/CA3099920A1/en active Pending
- 2019-05-31 IL IL305431A patent/IL305431B2/en unknown
- 2019-05-31 WO PCT/US2019/035015 patent/WO2019232449A1/en not_active Ceased
- 2019-05-31 EP EP19732510.3A patent/EP3801632A1/en active Pending
- 2019-05-31 KR KR1020207035785A patent/KR20210016375A/ko not_active Ceased
- 2019-05-31 IL IL316090A patent/IL316090A/en unknown
- 2019-05-31 TW TW108118955A patent/TW202015739A/zh unknown
- 2019-05-31 CN CN201980036786.3A patent/CN112218663B/zh active Active
- 2019-05-31 BR BR112020024549-6A patent/BR112020024549A2/pt unknown
-
2020
- 2020-11-26 PH PH12020500672A patent/PH12020500672A1/en unknown
- 2020-11-30 CL CL2020003117A patent/CL2020003117A1/es unknown
- 2020-11-30 US US17/247,117 patent/US11352348B2/en active Active
- 2020-12-22 CO CONC2020/0016137A patent/CO2020016137A2/es unknown
-
2021
- 2021-09-10 CL CL2021002377A patent/CL2021002377A1/es unknown
- 2021-09-10 CL CL2021002378A patent/CL2021002378A1/es unknown
-
2022
- 2022-05-03 US US17/661,909 patent/US11945807B2/en active Active
-
2023
- 2023-05-31 JO JOJO/P/2023/0124A patent/JOP20230124A1/ar unknown
- 2023-05-31 JO JOJO/P/2023/0123A patent/JOP20230123A1/ar unknown
- 2023-11-20 JP JP2023196433A patent/JP7753317B2/ja active Active
-
2024
- 2024-02-19 US US18/581,307 patent/US12514926B2/en active Active
- 2024-04-19 CL CL2024001239A patent/CL2024001239A1/es unknown
- 2024-04-19 CL CL2024001241A patent/CL2024001241A1/es unknown
- 2024-04-19 CL CL2024001240A patent/CL2024001240A1/es unknown
- 2024-04-19 CL CL2024001243A patent/CL2024001243A1/es unknown
- 2024-04-19 CL CL2024001242A patent/CL2024001242A1/es unknown
- 2024-09-10 US US18/830,446 patent/US20250135017A1/en active Pending
-
2025
- 2025-10-01 JP JP2025165244A patent/JP2026004432A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532063A5 (enExample) | ||
| JP2022512401A5 (enExample) | ||
| JP5925684B2 (ja) | 抗ｇｃｃ分子と関連組成物および方法 | |
| CN108026123B (zh) | 用于偶联的亲水链接体 | |
| RU2685728C2 (ru) | Конъюгат лиганд - цитотоксическое лекарственное средство, способ его получения и его применения | |
| ES2874306T3 (es) | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 | |
| KR102023496B1 (ko) | 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도 | |
| US7067131B2 (en) | Methods for using anti-MUC18 antibodies | |
| ES2818575T3 (es) | Reducción selectiva de anticuerpos con modificación de cisteínas | |
| ES2795818T3 (es) | Anticuerpos CD48 y conjugados de los mismos | |
| CN106414465B (zh) | 带电荷链接体及其在共轭反应上的应用 | |
| RU2018134331A (ru) | Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения | |
| JP2023500875A5 (enExample) | ||
| RU2018119296A (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| JP7570329B2 (ja) | ハーボキシジエンスプライシング調節薬抗体－薬物コンジュゲート及びその使用方法 | |
| JP2012522512A5 (enExample) | ||
| RU2014148162A (ru) | Анти-pmel17 антитела и их иммуноконъюгаты | |
| JP2018537975A5 (enExample) | ||
| TW201905000A (zh) | 含有抗globo h抗體之抗體－藥物共軛物及其用途 | |
| CN113453724B (zh) | 基于磺酰基马来酰亚胺的连接子和相应的偶联物 | |
| JPWO2023033129A5 (enExample) | ||
| JP2016511257A (ja) | 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与 | |
| NZ771328B2 (en) | Splicing modulator antibody-drug conjugates and methods of use | |
| RU2024115226A (ru) | Конъюгаты антитела и лекарственного средства, содержащие модулятор сплайсинга на основе гербоксидиена, и способы их применения | |
| NZ771328A (en) | Splicing modulator antibody-drug conjugates and methods of use |